These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 34996468)
1. Short-term melatonin supplementation decreases oxidative stress but does not affect left ventricular structure and function in myxomatous mitral valve degenerative dogs. Pongkan W; Piamsiri C; Dechvongya S; Punyapornwitthaya V; Boonyapakorn C BMC Vet Res; 2022 Jan; 18(1):24. PubMed ID: 34996468 [TBL] [Abstract][Full Text] [Related]
2. Serotonin concentrations in platelets, plasma, mitral valve leaflet, and left ventricular myocardial tissue in dogs with myxomatous mitral valve disease. Cremer SE; Singletary GE; Olsen LH; Wallace K; Häggström J; Ljungvall I; Höglund K; Reynolds CA; Pizzinat N; Oyama MA J Vet Intern Med; 2014; 28(5):1534-40. PubMed ID: 25146933 [TBL] [Abstract][Full Text] [Related]
3. Dietary intervention reduces left atrial enlargement in dogs with early preclinical myxomatous mitral valve disease: a blinded randomized controlled study in 36 dogs. Li Q; Heaney A; Langenfeld-McCoy N; Boler BV; Laflamme DP BMC Vet Res; 2019 Nov; 15(1):425. PubMed ID: 31775756 [TBL] [Abstract][Full Text] [Related]
4. Sildenafil improves heart rate variability in dogs with asymptomatic myxomatous mitral valve degeneration. Pirintr P; Saengklub N; Limprasutr V; Sawangkoon S; Kijtawornrat A J Vet Med Sci; 2017 Sep; 79(9):1480-1488. PubMed ID: 28717064 [TBL] [Abstract][Full Text] [Related]
5. Effect of atorvastatin on oxidative stress and inflammation markers in myxomatous mitral valve disease in dogs: A comparison of subclinical and clinical stages. Thassakorn P; Patchanee P; Pongkan W; Chattipakorn N; Boonyapakorn C J Vet Pharmacol Ther; 2019 May; 42(3):258-267. PubMed ID: 30666669 [TBL] [Abstract][Full Text] [Related]
6. Proteomics reveals plasma protein SERPINH1 as a potential diagnostic biomarkers for myxomatous mitral valve disease stage B2. Zhou Q; Wu Z; Li L; Zhou H; Chen Y; Guo S; Guo Y; Ma X; Zhang J; Feng W; Cui X; Qiu C; Xu M; Deng G J Proteomics; 2023 Jun; 282():104924. PubMed ID: 37146676 [TBL] [Abstract][Full Text] [Related]
7. Antioxidant capacity of lipid- and water-soluble antioxidants in dogs with subclinical myxomatous mitral valve degeneration anaesthetised with propofol or sevoflurane. Tomsič K; Nemec Svete A; Nemec A; Domanjko Petrič A; Pirman T; Rezar V; Vovk T; Seliškar A BMC Vet Res; 2020 Aug; 16(1):305. PubMed ID: 32831105 [TBL] [Abstract][Full Text] [Related]
8. Markers of Oxidative Stress in Dogs with Myxomatous Mitral Valve Disease are Influenced by Sex, Neuter Status, and Serum Cholesterol Concentration. Reimann MJ; Häggström J; Møller JE; Lykkesfeldt J; Falk T; Olsen LH J Vet Intern Med; 2017 Mar; 31(2):295-302. PubMed ID: 28132441 [TBL] [Abstract][Full Text] [Related]
9. Iron parameters analysis in dogs with myxomatous mitral valve disease. Kumiega E; A Kobak K; Noszczyk-Nowak A; Kasztura M BMC Vet Res; 2024 May; 20(1):210. PubMed ID: 38762716 [TBL] [Abstract][Full Text] [Related]
10. Differentially expressed platelet activation-related genes in dogs with stage B2 myxomatous mitral valve disease. Zhou Q; Cui X; Zhou H; Guo S; Wu Z; Li L; Zhang J; Feng W; Guo Y; Ma X; Chen Y; Qiu C; Xu M; Deng G BMC Vet Res; 2023 Dec; 19(1):271. PubMed ID: 38087280 [TBL] [Abstract][Full Text] [Related]
11. Plasma humanin as a prognostic biomarker for canine myxomatous mitral valve disease: a comparison with plasma NT-roBNP. Mangkhang K; Punyapornwithaya V; Tankaew P; Pongkan W; Chattipakorn N; Boonyapakorn C Pol J Vet Sci; 2018 Dec; 21(4):673-680. PubMed ID: 30605282 [TBL] [Abstract][Full Text] [Related]
12. Protective effects of omega-3 fatty acids in dogs with myxomatous mitral valve disease stages B2 and C. Nasciutti PR; Moraes AT; Santos TK; Gonçalves Queiroz KK; Costa APA; Amaral AR; Fernando Gomes Olivindo R; Pontieri CFF; Jeremias JT; Vendramini THA; Brunetto MA; Carvalho ROA PLoS One; 2021; 16(7):e0254887. PubMed ID: 34265016 [TBL] [Abstract][Full Text] [Related]
13. Utility of focused cardiac ultrasonography training in veterinary students to differentiate stages of subclinical myxomatous mitral valve disease in dogs. Huh T; Achilles EJ; Massey LK; Loughran KA; Larouche-Lebel É; Convey V; McKaba VF; Crooks A; Kraus MS; Gelzer AR; Oyama MA J Vet Intern Med; 2024; 38(3):1325-1333. PubMed ID: 38532734 [TBL] [Abstract][Full Text] [Related]
14. Left atrial deformation and phasic function determined by two-dimensional speckle-tracking echocardiography in dogs with myxomatous mitral valve disease. Caivano D; Rishniw M; Birettoni F; Patata V; Giorgi ME; Porciello F J Vet Cardiol; 2018 Apr; 20(2):102-114. PubMed ID: 29459124 [TBL] [Abstract][Full Text] [Related]
15. Can cartilage intermediate layer protein 1 (CILP1) use as a novel biomarker for canine myxomatous mitral valve degeneration levels or not? Kim HJ; Kim J; Kim S; Kim HJ BMC Vet Res; 2023 Mar; 19(1):59. PubMed ID: 36882760 [TBL] [Abstract][Full Text] [Related]
16. Pulmonary-vein-to-pulmonary-artery ratio can be utilized to evaluate myxomatous mitral valve disease progression in dogs. Kim MS; Kim J; Seo MW; Park C Am J Vet Res; 2024 Jul; 85(7):. PubMed ID: 38663446 [TBL] [Abstract][Full Text] [Related]
17. Left Atrial Strain at Different Stages of Myxomatous Mitral Valve Disease in Dogs. Nakamura K; Kawamoto S; Osuga T; Morita T; Sasaki N; Morishita K; Ohta H; Takiguchi M J Vet Intern Med; 2017 Mar; 31(2):316-325. PubMed ID: 28145607 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of antioxidant status and lipid peroxidation in dogs with myxomatous mitral valve degeneration stage B1. Tomsič K; Domanjko Petrič A; Nemec A; Pirman T; Rezar V; Seliškar A; Vovk T; Nemec Svete A Front Vet Sci; 2023; 10():1203480. PubMed ID: 37745214 [TBL] [Abstract][Full Text] [Related]
19. Myxomatous mitral valve disease in Labrador Retrievers and Golden Retrievers. Wilson BA; Wesselowski S J Am Vet Med Assoc; 2024 Nov; 262(11):1467-1475. PubMed ID: 38906175 [TBL] [Abstract][Full Text] [Related]
20. Mitral valve morphology assessed by three-dimensional transthoracic echocardiography in healthy dogs and dogs with myxomatous mitral valve disease. Menciotti G; Borgarelli M; Aherne M; Wesselowski S; Häggström J; Ljungvall I; Lahmers SM; Abbott JA J Vet Cardiol; 2017 Apr; 19(2):113-123. PubMed ID: 28279678 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]